$Quantum-Si Inc.(QSI)$ have huge upside potential, despite the recent volatility and potential year-end pressures:

Stock Offering Impact: The stock offering announcement at $2.26 per share to raise $75M caused a sharp retrace - significant downwards movement. The Stock offering came at a right time, though slightly late, to raise capital for more R&D.

Room for Recovery and Growth: during COVID-19, most pharma R&D was redirected to vaccine research, delaying other projects. With the pandemic over and R&D resuming, QSI is well-positioned to benefit from the renewed focus on biotech, particularly in personalized medicine and drug discovery, offering significant growth potential.

EPS Outperformance: Consistently beating EPS estimates highlights operational efficiency and strong execution, reinforcing investor trust.

Strong Collaboration Partners: Collaborations with SkyWater Technology and NVIDIA enhance its technological edge and scalability. The launch of Proteovue establishes Quantum-Si as a leader in next-generation protein sequencing, with high potential in biotech and research sectors.

TLDR: QSI is well-positioned for growth with its cutting-edge proteomics technology. Despite recent volatility, including a stock offering and downturn, tstrategic moves like the launch of Proteovue and collaborations with SkyWater and NVIDIA put its in an advantageous position. With pharma R&D shifting focus back to areas beyond COVID-19 vaccines, QSI stands to benefit greatly, especially if its R&D delivers breakthroughs in drug discovery and personalized medicine. This puts QSI in a prime position for long-term value, potentially becoming a crucial player in the pharmaceutical industry.

Fair Valuation: $1.75-$2.

#stockstowatch2026 #QuantumSi #QSI #BiotechInnovation #Proteomics #PharmaR&D #PostCovidRecovery #GrowthPotential #StockMarket #TigerBrokers